BlackRock (NYSE: BLK) holds 5.39M shares of Corvus Pharmaceuticals (CRVS)

Rhea-AI Filing Summary

BlackRock, Inc. amends a Schedule 13G to report ownership of 5,387,818 shares of Corvus Pharmaceuticals common stock, representing 6.4% of the class. The filing shows sole voting power for 5,320,965 shares and sole dispositive power for 5,387,818 shares as reported on 04/27/2026.

The amendment cites aggregated holdings across BlackRock reporting business units and notes various clients/beneficiaries may have rights to dividends or proceeds. Exhibit references include a Power of Attorney and an Item 7 exhibit identifying relevant subsidiaries.

Insights

Institutional Ownership Analyst

BlackRock reports a 6.4% passive stake through reporting business units.

The amendment documents aggregated beneficial ownership of 5,387,818 shares, with sole voting and dispositive counts nearly identical. This presentation is typical for passive institutional holders that report under Schedule 13G/A rather than 13D.

Key dependencies include allocation among BlackRock business units and any underlying client arrangements; subsequent filings or Exhibits (Item 7) will clarify which subsidiaries hold the securities.

Governance & Proxy Specialist

Disclosure signals passive holding without active control statements.

The filing states voting and dispositive powers held by BlackRock units but does not claim control; Item 6 notes no single third party holds >5% of the shares via the reported accounts. The power-of-attorney exhibit and Item 7 exhibit may further define the reporting structure.

Monitor future amendments if BlackRock changes its ownership percentage above regulatory thresholds or files a Schedule 13D.

Key Figures

Beneficial ownership: 5,387,818 shares Percent of class: 6.4% Sole voting power: 5,320,965 shares +2 more

5 metrics

Beneficial ownership 5,387,818 shares Amount beneficially owned reported in Item 4(a)

Percent of class 6.4% Percent of class reported in Item 4(b)

Sole voting power 5,320,965 shares Item 4(c)(i) sole power to vote or direct vote

Sole dispositive power 5,387,818 shares Item 4(c)(iii) sole power to dispose or direct disposition

Signature date 04/27/2026 Filer signature date on amendment

Key Terms

Schedule 13G/A, beneficially owned, sole dispositive power, Exhibit 24

4 terms

Schedule 13G/A regulatory

"Amendment No. 1 and cover language referencing aggregated Reporting Business Units"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Item 4(a) — Amount beneficially owned: 5387818"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Item 4(c)(iii) — Sole power to dispose or to direct the disposition of: 5387818"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Exhibit 24 regulatory

"Exhibit Information Exhibit 24: Power of Attorney"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

CORVUS PHARMACEUTICALS INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

221015100

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 221015100

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,320,965.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,387,818.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,387,818.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.4 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CORVUS PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: 901 Gateway Boulevard, Third Floor South San Francisco CA 94080
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 221015100
Item 4.	Ownership
(a)	Amount beneficially owned: 5387818
(b)	Percent of class: 6.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5320965
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5387818
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of CORVUS PHARMACEUTICALS INC. No one person's interest in the common stock of CORVUS PHARMACEUTICALS INC is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	04/27/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7

FAQ

What stake does BlackRock report in CORVS?

BlackRock reports beneficial ownership of 5,387,818 shares, representing 6.4% of Corvus Pharmaceuticals common stock. The amount and percentage appear in the Item 4 ownership section of the amendment.

Does BlackRock have voting control over CORVS shares?

The filing shows sole voting power for 5,320,965 shares and sole dispositive power for 5,387,818 shares. These figures are disclosed under Item 4(a) and Item 4(c)(i)/(iii).

Is this a passive Schedule 13G or an active 13D filing for CORVS?

This submission is an Amendment to Schedule 13G, indicating reporting as a passive institutional holder rather than an active Schedule 13D investor. The cover language references aggregated reporting business units.

Who signed the amendment for BlackRock?

The amendment is signed by Spencer Fleming, listed as Managing Director, with a signature date of 04/27/2026 on the filing cover page.

What exhibits accompany the filing?

The amendment references Exhibit 24 (Power of Attorney) and Exhibit 99 (Item 7 identification of subsidiaries). These exhibits clarify filing authority and subsidiary identification.